



LIVINGSTONE HEALTH HOLDINGS LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration Number 200404283C)

UPDATE ON USE OF PROCEEDS

The board of directors (“**Board**” or “**Directors**”) of Livingstone Health Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the announcements made by the Company in relation to the Rights cum Warrants Issue on 27 March 2024, 30 April 2024, 13 May 2024, 30 May 2024, 11 June 2024, 2 July 2024, 4 July 2024, 1 August 2024, 30 August 2024, 3 September 2024, 5 September 2024, 6 September 2024, 18 September 2024, 23 September 2024, 25 September 2024, 30 September 2024, 7 October 2024, 15 October 2024, 24 October 2024, 14 October 2025 and 17 November 2025 (the “**Previous Announcements**”). Unless otherwise defined, all terms and references used herein shall bear the same meanings ascribed to them in the Previous Announcements.

The Board wishes to provide an update on the utilisation of the net proceeds from the Rights cum Warrants Issue (the “**Net Proceeds**”).

On 1 December 2025, the Company utilised the balance of the Net Proceeds amounting to S\$322,000 for the purchase consideration in relation to the acquisition of 20% of Affinity Surgery Centre Pte. Ltd. (further details of which are set out in the announcement made by the Company on 21 November 2025).

In this regard, the status of the use of the Net Proceeds as at the date of this announcement is as follows:

Intended use of net proceeds	Balance brought forward ⁽¹⁾ (S\$'000)	Additional proceeds from Warrant exercises ⁽²⁾ (S\$'000)	Amount utilised (S\$'000)	Balance (S\$'000)
General working capital requirements	-	-	-	-
Business growth, acquisitions and expansion	303	19	(322)	-
Total	303	19	(322)	-

Notes:

- (1) Balance of the unutilised amount brought forward from 30 September 2025, as at the date of the Company's financial results announcement for the six-month financial period ended 30 September 2025.
- (2) Arising from the exercise of an aggregated 747,856 Warrants announced on 14 October 2025 and 17 November 2025 at the Exercise Price of S\$0.025 per share.

The use of Net Proceeds disclosed above is in accordance with the intended uses as disclosed in the announcement made by the Company on 27 March 2024 and the Offer Information Statement.

Accordingly, as at the date of this announcement, the Board wishes to update that the Company has fully utilised all of the Net Proceeds.

By Order of the Board

Dr Tay Ching Yit, Wilson
Executive Director and Chief Executive Officer
1 December 2025

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Lee Khai Yinn (Telephone: (65) 6232 3210) at 1 Robinson Road, #21-01, AIA Tower, Singapore 048542.*